Supplementary materials: Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

These are peer-reviewed supplementary materials for the article 'Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema' published in the Journal of Comparative Effectiveness Research.Supplementary dataSupplementary Table 1: Inclusion and exclusion criteria for the 2018 SLR.Supplementary Table 2: Trial design of the studies in the evidence network.Supplementary methodsStatistical details on methodologyAim: With no head-to-head studies comparing the effectiveness of lanadelumab and berotralstat for prevention of hereditary angioedema (HAE) attacks, this networkmeta-analysis (NMA) aimed to indirectly compare the effectiveness of these treatments. Materials & methods: The NMA, using the published data from Phase III trials, was performed using a frequentist weighted regression-based approach following Rucker et al. Efficacy outcomes of interest were HAE attack rate per 28 days and ≥90% reduction in monthly HAE attacks. Results & conclusion: In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.

本数据集为发表在《比较疗效研究杂志》上的文章《用于治疗遗传性血管性水肿的兰达鲁单抗与贝罗他司他之间的间接比较网络荟萃分析》的同行评审补充材料。补充数据：补充表1：2018年系统评价的纳入和排除标准；补充表2：证据网络中研究的试验设计；补充方法：统计方法细节。研究目的：鉴于尚无直接比较兰达鲁单抗与贝罗他司他预防遗传性血管性水肿（HAE）发作有效性的头对头研究，本研究旨在通过网络荟萃分析（NMA）间接比较这两种治疗的有效性。材料与方法：采用鲁克等人的频率加权回归方法，利用III期临床试验已发表的资料进行了NMA。关注的疗效结局为每28天HAE发作率和每月HAE发作次数≥90%的减少。结果与结论：在本NMA中，每两周或每月一次给予兰达鲁单抗300 mg，与每日一次贝罗他司他150 mg或110 mg相比，在评估的两种疗效结局中均显示出统计学上显著更高的有效性。